Cargando…
Prices of combination medicines and single‐molecule antihypertensive medicines in India's private health care sector
More than half of patients with hypertension require two or more medicines to control blood pressure. Combinations of anti‐hypertensive medicines are available as Single Pill Combinations (SPCs) or Single Agent Pills (SAPs). SPCs of two or more anti‐hypertensive medicines facilitate simpler dosing s...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678655/ https://www.ncbi.nlm.nih.gov/pubmed/33369089 http://dx.doi.org/10.1111/jch.14143 |
_version_ | 1784616352321896448 |
---|---|
author | Negi, Sagri Neupane, Dinesh Sahoo, Swagata Kumar Mahajan, Tanushree Swaroop, Kishan Moran, Andrew E. Sharma, Bhawna Pathni, Anupam Khungar |
author_facet | Negi, Sagri Neupane, Dinesh Sahoo, Swagata Kumar Mahajan, Tanushree Swaroop, Kishan Moran, Andrew E. Sharma, Bhawna Pathni, Anupam Khungar |
author_sort | Negi, Sagri |
collection | PubMed |
description | More than half of patients with hypertension require two or more medicines to control blood pressure. Combinations of anti‐hypertensive medicines are available as Single Pill Combinations (SPCs) or Single Agent Pills (SAPs). SPCs of two or more anti‐hypertensive medicines facilitate simpler dosing schedules, decrease pill burden, increase adherence to medicine, and simplify procurement and distribution. Despite this, equivalent combinations of separate pills (SAPs) are often prescribed instead of SPCs under the assumption that SAPs are priced lower. This study compared prices of anti‐hypertensive SPCs and equivalent SAPs in the private health care sector of India. High sales volume anti‐hypertensive SPCs and SAPs were selected from 2018 private sector pharmaceutical sales data. SPCs and SAPs price information was collected from online pharmacy websites between November 2019 and January 2020. Anti‐hypertensive SPCs represent approximately 39.1% of India's private sector anti‐hypertensive drug market. Multiple manufacturers produce the same top‐selling SPCs, suggesting a viable and competitive market. A comparison of SPCs and SAPs across different manufacturers showed that the lowest prices of both SPCs and the sum of component SAPs were nearly identical across different manufacturers. An analysis of dual‐drug SPCs and SAPs by the same manufacturer showed that most manufacturers (five of six) had priced their SPCs higher than SAPs. These observations suggest that the price of SPCs could be lowered to match the combined price of the component SAPs, and manufacturing costs and market forces do not present a barrier to the implementation of anti‐hypertensive SPCs. |
format | Online Article Text |
id | pubmed-8678655 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86786552021-12-23 Prices of combination medicines and single‐molecule antihypertensive medicines in India's private health care sector Negi, Sagri Neupane, Dinesh Sahoo, Swagata Kumar Mahajan, Tanushree Swaroop, Kishan Moran, Andrew E. Sharma, Bhawna Pathni, Anupam Khungar J Clin Hypertens (Greenwich) Original Papers More than half of patients with hypertension require two or more medicines to control blood pressure. Combinations of anti‐hypertensive medicines are available as Single Pill Combinations (SPCs) or Single Agent Pills (SAPs). SPCs of two or more anti‐hypertensive medicines facilitate simpler dosing schedules, decrease pill burden, increase adherence to medicine, and simplify procurement and distribution. Despite this, equivalent combinations of separate pills (SAPs) are often prescribed instead of SPCs under the assumption that SAPs are priced lower. This study compared prices of anti‐hypertensive SPCs and equivalent SAPs in the private health care sector of India. High sales volume anti‐hypertensive SPCs and SAPs were selected from 2018 private sector pharmaceutical sales data. SPCs and SAPs price information was collected from online pharmacy websites between November 2019 and January 2020. Anti‐hypertensive SPCs represent approximately 39.1% of India's private sector anti‐hypertensive drug market. Multiple manufacturers produce the same top‐selling SPCs, suggesting a viable and competitive market. A comparison of SPCs and SAPs across different manufacturers showed that the lowest prices of both SPCs and the sum of component SAPs were nearly identical across different manufacturers. An analysis of dual‐drug SPCs and SAPs by the same manufacturer showed that most manufacturers (five of six) had priced their SPCs higher than SAPs. These observations suggest that the price of SPCs could be lowered to match the combined price of the component SAPs, and manufacturing costs and market forces do not present a barrier to the implementation of anti‐hypertensive SPCs. John Wiley and Sons Inc. 2020-12-24 /pmc/articles/PMC8678655/ /pubmed/33369089 http://dx.doi.org/10.1111/jch.14143 Text en © 2020 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Papers Negi, Sagri Neupane, Dinesh Sahoo, Swagata Kumar Mahajan, Tanushree Swaroop, Kishan Moran, Andrew E. Sharma, Bhawna Pathni, Anupam Khungar Prices of combination medicines and single‐molecule antihypertensive medicines in India's private health care sector |
title | Prices of combination medicines and single‐molecule antihypertensive medicines in India's private health care sector |
title_full | Prices of combination medicines and single‐molecule antihypertensive medicines in India's private health care sector |
title_fullStr | Prices of combination medicines and single‐molecule antihypertensive medicines in India's private health care sector |
title_full_unstemmed | Prices of combination medicines and single‐molecule antihypertensive medicines in India's private health care sector |
title_short | Prices of combination medicines and single‐molecule antihypertensive medicines in India's private health care sector |
title_sort | prices of combination medicines and single‐molecule antihypertensive medicines in india's private health care sector |
topic | Original Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678655/ https://www.ncbi.nlm.nih.gov/pubmed/33369089 http://dx.doi.org/10.1111/jch.14143 |
work_keys_str_mv | AT negisagri pricesofcombinationmedicinesandsinglemoleculeantihypertensivemedicinesinindiasprivatehealthcaresector AT neupanedinesh pricesofcombinationmedicinesandsinglemoleculeantihypertensivemedicinesinindiasprivatehealthcaresector AT sahooswagatakumar pricesofcombinationmedicinesandsinglemoleculeantihypertensivemedicinesinindiasprivatehealthcaresector AT mahajantanushree pricesofcombinationmedicinesandsinglemoleculeantihypertensivemedicinesinindiasprivatehealthcaresector AT swaroopkishan pricesofcombinationmedicinesandsinglemoleculeantihypertensivemedicinesinindiasprivatehealthcaresector AT moranandrewe pricesofcombinationmedicinesandsinglemoleculeantihypertensivemedicinesinindiasprivatehealthcaresector AT sharmabhawna pricesofcombinationmedicinesandsinglemoleculeantihypertensivemedicinesinindiasprivatehealthcaresector AT pathnianupamkhungar pricesofcombinationmedicinesandsinglemoleculeantihypertensivemedicinesinindiasprivatehealthcaresector |